[1][3] The important point is that GLP-1 storage is not one single rule
When published, weight change results from the DAPA-CKD trial [39] will probably enable further correlations between weight loss and renal outcomes
It works by reducing appetite, improving blood sugar, and lowering risk of cardiovascular disease (heart disease, heart attack, and stroke)
Over a mean follow-up of approximately 33 months, semaglutide 2.4 mg reduced MACE by 20% (hazard ratio 0.80)
Waist circumference fell by an average of 24.1 cm at the top dose
Potential Benefits Patients may experience benefits such as: Individual results vary and depend on many factors, including treatment adherence, nutrition, physical activity, and overall health